Oroglic 80 Tablet contains Gliclazide 80 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. Gliclazide acts by stimulating insulin secretion from the pancreatic beta cells, thereby improving glycemic control in patients with non-insulin-dependent diabetes. It is particularly effective in reducing fasting and postprandial blood glucose levels. Oroglic 80 is prescribed as part of a comprehensive diabetes management plan that includes diet, exercise, and weight control. The medication is typically administered once daily with breakfast to optimize efficacy and minimize the risk of hypoglycemia. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to sulfonylureas. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Regular monitoring of blood glucose levels and periodic assessment of renal and hepatic function are recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Oroglic 80 should be used cautiously in elderly patients and those with cardiovascular disease. Patient education on recognizing and managing hypoglycemia is essential to ensure safe and effective treatment outcomes.